Skip to main content

Table 4 Intention-to-treat analysis of changes in prescribing rates showing sum scores per clinical topic and scores per drug

From: Effect of audit and feedback with peer review on general practitioners’ prescribing and test ordering performance: a cluster-randomized controlled trial

 

Intervention

Control

    

Clinical topic

n

Mean before (sd)

Mean after (sd)

n

Mean before (sd)

Mean after (sd)

Ba (95% CI)

icc

Direction

p

Anaemia

 Iron preparations, oral

39

25.0 (20.7)

45.1 (40.0)

49

27.4 (28.4)

49.2 (55.7)

3.9 (−13.9, 21.5)

0.21

=

0.644

Urinary tract infections

 Antibiotics UTI

39

43.5 (31.6)

47.3 (36.5)

49

47.5 (38.7)

59.7 (48.7)

11.9 (−3.2, 27.0)

0.21

↓

0.113

 Prostate complaints

39

59.1 (43.3)

107.1 (69.6)

49

66.5 (58.6)

127.5 (102.2)

20.0 (−20.9, 60.8)

0.38

↓

0.306

 Alpha receptor blockers

39

49.6 (35.7)

86.6 (56.2)

49

55.0 (49.5)

103.3 (81.5)

18.5 (−15.3, 52.3)

0.42

↓

0.258

 5 alpha reductase inhibitors

39

9.5 (9.5)

20.4 (18.6)

49

11.5 (11.2)

24.2 (24.7)

1.4 (−7.2, 10.0)

0.01

↓

0.735

 Stomach complaints

49

329.7 (286.9)

612.0 (477.0)

39

282.6 (210.1)

491.8 (333.4)

106.7 (−70.7, 284.2)

0.63

↓

0.219

 H2 antagonists

49

27.8 (26.4)

32.4 (30.0)

39

22.3 (20.5)

21.3 (16.4)

12.5 (−1.8, 26.8)

0.44

↑

0.081

 Proton pump inhibitors

49

300.8 (262.9)

578.3 (452.3)

39

259.4 (192.3)

469.1 (322.1)

93.7 (−71.9, 259.4)

0.62

↓

0.246

 Misoprostol

49

0.1 (0.4)

0.0 (0.2)

39

0.1 (0.4)

0.2 (0.5)

−0.1 (−0.2,−0.0)

0.00

↓

0.008 b

 Triple therapy (ATC A02BD04)

49

1.0 (1.7)

1.3 (2.0)

39

0.9 (1.3)

1.1 (1.7)

0.2 (−0.7, 1.2)

0.49

↓

0.593 b

 Thyroid dysfunction

49

81.3 (66.3)

137.2 (102.6)

39

71.4 (48.9)

107.1 (71.6)

21.2 (−14.1, 56.6)

0.42

=

0.217

 Thyroid hormones

49

74.8 (60.8)

125.0 (92.6)

39

66.9 (47.4)

100.8 (70.0)

18.2 (−16.0, 52.4)

0.45

=

0.269

 Antithyroid preparations

49

6.5 (8.6)

12.2 (17.8)

39

4.5 (4.4)

6.3 (7.3)

2.6 (−1.7, 7.0)

0.09

↑

0.218 b

 Perimenopausal complaints

49

56.4 (42.7)

56.8 (41.8)

39

46.3 (34.2)

46.0 (29.6)

6.6 (−12.0, 25.2)

0.56

↓

0.459

 Oestrogens, oral

49

14.1 (13.6)

12.7 (12.1)

39

12.3 (11.8)

11.2 (10.4)

0.2 (−3.6, 4.1)

0.01

↓

0.889

 Contraceptives (>50y)

49

3.6 (3.2)

6.4 (4.9)

39

3.2 (3.9)

5.9 (4.2)

1.1 (−1.9, 4.2)

0.34

↓

0.431

 Hormone replacement therapy

49

34.8 (28.6)

34.7 (27.0)

39

28.3 (19.7)

26.3 (17.8)

5.8 (−6.5, 18.0)

0.70

↓

0.331

 Clonidine

49

0.5 (1.8)

0.5 (2.0)

39

0.2 (0.5)

0.4 (2.0)

0.1 (−1.0, 1.2)

0.13

↓

0.908 b

 Tibolon

49

3.4 (4.1)

2.4 (2.7)

39

2.3 (2.8)

2.2 (3.4)

−0.3 (−1.4, 0.8)

0.00

↓

0.615

  1. The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
  2. n = number of practices
  3. aAdjusted difference between groups at end of intervention, corrected for baseline
  4. bstatistically significant interaction
  5. Misoprostol
  6. P 10: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
  7. P 90: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
  8. Triple therapy (ATC A02BD04)
  9. P10: B (95% CI): 0.9 (−0.2, 1.9). p: 0.117
  10. P90: B (95% CI):−0.4 (−1.6, 0.7). p: 0.413
  11. Antithyroid preparations
  12. P10: B (95% CI):−1.9 (−7.2, 3.4). p: 0.474
  13. P90: B (95% CI): 12.3 (4.6, 19.9). p: 0.002
  14. Clonidine
  15. P10: B (95% CI): 0.6 (−0.4, 1.6). p: 0.215
  16. P90: B (95% CI):−2.4 (−3.9,−1.0). p: < 0.001
Back to article page

BMC Primary Care

ISSN: 2731-4553

Contact us